TLX is valued at $2B for several reasons, but primarily due to advanced development stage of is product candidates. One of these, Illuccix, is now a commercial product generating revenue given recent approval by the TGA in Australia. This suggests FDA is more likely to also approve Illuccix in late December. If this occurs they can aim for $30M revenue in US p.a. Then they have a second product coming, as well as some high value cancer therapy products. CU6 and RAD are good but very early stage. Plus TLX management is exceptional. As always PDYOR.
RAD Price at posting:
40.0¢ Sentiment: None Disclosure: Not Held
